Vaginal Symptoms in Primary Care: A Test-Directed Approach to Candidiasis, Bacterial Vaginosis, and Trichomoniasis

Introduction

Vaginal symptoms are common in outpatient practice, but classic symptom patterns are less specific than they may appear. Pruritus does not establish candidiasis. Malodor does not establish BV. Frothy or yellow-green discharge may raise suspicion for trichomoniasis but is neither sufficiently sensitive nor specific to confirm it. Many infected patients have mild or atypical symptoms, and noninfectious conditions can closely mimic infection.[1,4,9,10]

The central clinical question is not simply whether to prescribe fluconazole, metronidazole, or clindamycin. It is whether the patient has uncomplicated vaginitis, cervicitis, PID, a vulvar dermatosis, genitourinary syndrome of menopause, irritant or allergic disease, a retained foreign body, or mixed infection. Missing cervicitis or PID can delay treatment of conditions associated with infertility, chronic pelvic pain, and adverse pregnancy outcomes. Missing a noninfectious cause can lead to persistent symptoms and repeated unnecessary antimicrobial exposure.[1,4,10]

Test-directed management improves diagnostic precision and supports antimicrobial stewardship by reducing reflexive treatment based on symptoms alone. It also creates an opportunity to identify coinfection, obtain species-level Candida information when needed, and pursue targeted resistance testing in selected treatment failures. Routine vaginitis panels do not themselves provide antimicrobial susceptibility results, and resistance assessment should not be implied unless appropriate culture, susceptibility testing, or specialized testing has been performed.[4-7,12]

Why This Topic Matters Now

Three developments make diagnostic discipline particularly important. First, validated molecular vaginitis assays are increasingly available and can improve detection when microscopy is unavailable, delayed, or operator-dependent. Their performance varies by assay, specimen type, and study population, and BV NAATs are best established in symptomatic patients.[4,6,12]

Second, the preferred CDC regimen for trichomoniasis in women is metronidazole 500 mg orally twice daily for 7 days. This recommendation is supported by randomized evidence showing lower repeat positivity at a test-of-cure visit than with a single 2-g dose. The trial did not establish that the multidose regimen independently prevents reinfection; partner treatment and avoidance of re-exposure remain essential.[7,13,14]

Third, management of recurrent BV and recurrent VVC continues to evolve. A 2025 randomized trial found lower 12-week BV recurrence when women and their male partners were treated concurrently than when women alone received treatment. ACOG subsequently issued a focused update supporting consideration of concurrent partner therapy in selected patients, while CDC’s publicly available BV guidance still reflects the 2021 recommendation against routine partner treatment. Newer VVC agents provide additional options but have substantial reproductive restrictions that must be incorporated into patient selection.[2,3,6,17,19-23]

Primary care clinicians should also recognize that many patients self-treat before presentation. Over-the-counter azoles, intravaginal products, antibiotics, lubricants, menses, semen exposure, douching, and recent sexual activity can alter examination findings or test interpretation. A structured evaluation is more reliable than symptom recognition alone.[4]

Initial Clinical Assessment

The first task is to determine whether symptoms are consistent with uncomplicated lower genital tract disease or require broader evaluation. History should address symptom onset and duration; discharge amount and character; odor; vulvar pruritus, burning, or pain; external versus internal dysuria; dyspareunia; pelvic or abdominal pain; abnormal bleeding; fever; pregnancy status; recent antibiotic exposure; diabetes; immunosuppression; HIV status; sexual practices; sex of partners; new or multiple partners; condom use; vaginal hygiene practices, including douching; intravaginal medications or products; and recent self-treatment.[1,4,10]

A pelvic examination is generally appropriate when symptoms are new, severe, recurrent, persistent, diagnostically unclear, associated with pelvic pain or bleeding, or accompanied by STI risk. In selected lower-risk patients with access to validated self-collected vaginal swab testing, laboratory evaluation without speculum examination may be reasonable. Convenience should not replace examination when red flags or an alternative diagnosis are possible.[4,6,7,10,12]

Red flags include fever, pelvic pain, cervical motion or adnexal tenderness, mucopurulent cervicitis, genital ulcers or vesicles, pregnancy with concerning symptoms, postmenopausal bleeding, suspected retained foreign body, suspected sexual assault, severe vulvar dermatitis, immunocompromised status, or failure of appropriate therapy. These findings should prompt evaluation beyond uncomplicated vaginitis.

A Test-Directed Diagnostic Framework

A practical diagnostic framework includes vaginal pH, saline and potassium hydroxide microscopy when available, an amine or whiff test, and laboratory testing when bedside findings are negative, unavailable, or discordant with symptoms. In practices without reliable microscopy, validated molecular testing may be more useful than repeated empiric treatment.[4,6,7,12]

Vaginal pH is helpful but not diagnostic. A pH greater than 4.5 supports consideration of BV or trichomoniasis, although trichomoniasis can occur with a normal pH. Uncomplicated candidiasis is usually associated with a pH below 4.5. Blood, semen, cervical mucus, lubricants, medications, menopause, and collection technique can affect the result.[4-7]

Microscopy remains valuable when performed promptly and competently. Clue cells support BV; motile trichomonads support trichomoniasis; and budding yeast, hyphae, or pseudohyphae support VVC. Sensitivity is limited. A negative wet mount does not reliably exclude trichomoniasis or candidiasis in a symptomatic patient.[4,5,7]

For trichomoniasis, a nucleic acid amplification test (NAAT) is preferred when available, particularly if wet mount is negative or cannot be examined immediately. For complicated, recurrent, persistent, or nonresponsive VVC, culture or an appropriately validated molecular assay is useful because Candida glabrata may be missed on microscopy and species identification can guide management. For symptomatic BV, Amsel criteria, Nugent scoring, and validated NAATs are reasonable diagnostic methods. Culture for Gardnerella vaginalis is not recommended because it lacks specificity.[5-7,12]

Table 1. Diagnostic Approach to Common Vaginal Symptoms

Condition	Suggestive findings	Preferred confirmation	Important caveat
Vulvovaginal candidiasis	Pruritus, soreness, external dysuria, vulvar erythema, fissures, curdy discharge	KOH microscopy showing yeast forms; culture or validated molecular testing when complicated or microscopy is negative	Symptoms are nonspecific; Candida colonization without symptoms should not be treated
Bacterial vaginosis	Thin homogeneous discharge, odor, pH greater than 4.5, clue cells, positive whiff test	Amsel criteria, Nugent score, or validated NAAT in symptomatic patients	BV NAAT accuracy is best established in symptomatic patients; Gardnerella culture is not diagnostic
Trichomoniasis	Discharge, odor, irritation, dysuria, elevated pH, possible cervicitis	NAAT preferred; immediate wet mount if available	Wet-mount sensitivity is limited and declines rapidly after collection
Cervicitis or PID	Mucopurulent discharge, bleeding, pelvic pain, cervical motion or adnexal tenderness	Gonorrhea and chlamydia NAAT, pregnancy testing, and pelvic evaluation as indicated	Do not misclassify cervicitis or PID as uncomplicated vaginitis
Noninfectious vaginitis or vulvar disease	Irritant exposure, dermatitis, atrophy, burning, pain, dyspareunia	Examination-directed diagnosis; referral or biopsy when indicated	Repeated negative infectious testing should trigger diagnostic reconsideration

Vulvovaginal Candidiasis

Candida albicans causes most VVC, but non-albicans species are clinically important in recurrent, persistent, or treatment-resistant disease. Typical symptoms include vulvar pruritus, soreness, external dysuria, dyspareunia, erythema, fissures, excoriations, and sometimes thick discharge. These findings support the diagnosis but do not establish it.[5,11,16]

Uncomplicated VVC is sporadic or infrequent, mild to moderate, likely caused by C. albicans, and occurs in a nonimmunocompromised patient. Complicated VVC includes recurrent or severe VVC, non-albicans candidiasis, poorly controlled diabetes, immunocompromising conditions, immunosuppressive therapy, or poor response to standard treatment. Pregnancy is not part of the CDC classification box for complicated VVC, but it materially changes treatment selection.[5]

Uncomplicated VVC

For uncomplicated VVC in an appropriate nonpregnant patient, short-course topical azoles or fluconazole 150 mg orally once are standard options. Treatment selection should consider pregnancy status or reproductive potential, drug interactions, hepatic disease, renal function, QT risk, patient preference, cost, and prior response. Topical therapy limits systemic exposure and may be preferred when oral azole interactions are a concern. Oil-based intravaginal products may weaken latex condoms or diaphragms, so product-specific labeling should be reviewed.[5,21]

Persistent symptoms after over-the-counter therapy or recurrence within 2 months should prompt clinical evaluation and testing rather than repeated self-treatment. Probiotics and homeopathic products should not replace established therapy because evidence supporting their use for treatment of VVC is insufficient.[5]

Pregnancy

Pregnancy changes management. CDC recommends only topical azole therapy applied for 7 days. Oral fluconazole should not be used for VVC during pregnancy. Epidemiologic studies have suggested associations between first-trimester exposure, including a 150-mg dose, and spontaneous abortion or congenital abnormalities, while higher or prolonged doses have a clearer fetal-harm concern in labeling.[5,21]

Recurrent VVC

CDC commonly defines recurrent VVC as three or more symptomatic episodes in less than 1 year. Diagnosis should be confirmed with culture or an appropriately validated molecular test, ideally with species identification. For recurrent C. albicans VVC, a longer induction regimen is recommended before maintenance therapy. Options include 7 to 14 days of topical treatment or fluconazole on days 1, 4, and 7, followed by fluconazole once weekly for 6 months when appropriate.[5,16,18]

Maintenance fluconazole can control symptoms during therapy, but durable cure remains difficult. In a pivotal trial, disease-free rates declined after maintenance therapy ended. Persistent culture-positive symptoms despite maintenance should prompt susceptibility testing when available and specialist consultation.[5,18]

Non-albicans Candida

A positive culture for non-albicans Candida does not always establish causality because colonization or minimally symptomatic carriage can occur. Clinicians should exclude other causes of symptoms before attributing persistent vaginitis to the isolate. Conventional therapy is often less effective for non-albicans VVC, and susceptibility varies by species.[5,16]

CDC recommends a 7- to 14-day course of a nonfluconazole azole regimen for symptomatic non-albicans VVC. If recurrence occurs, vaginal boric acid 600 mg daily for 3 weeks is a guideline-listed option, with referral when symptoms recur. Because this is an intravaginal treatment used in a setting with limited evidence, clinicians should confirm patient suitability and provide clear administration counseling.[5]

Newer Agents

Oteseconazole is FDA approved to reduce the incidence of recurrent VVC in females with a history of RVVC who are not of reproductive potential. It is contraindicated in females of reproductive potential, pregnancy, and lactation. Labeling also advises against use in severe renal impairment or end-stage renal disease and in moderate or severe hepatic impairment. These restrictions are central to patient selection.[19,23]

Ibrexafungerp is a nonazole antifungal FDA approved for treatment of VVC and for reduction in the incidence of recurrent VVC. It carries a boxed warning for embryo-fetal toxicity and is contraindicated in pregnancy. Pregnancy must be excluded before treatment in patients of reproductive potential, and reassessment is recommended before each monthly dose when used for RVVC reduction. Effective contraception is advised during treatment and for 4 days after the last dose. Strong CYP3A inhibitors require dose modification, and strong or moderate CYP3A inducers should generally be avoided according to labeling.[20,22]

These agents should be used for appropriately selected patients after diagnostic confirmation, not as substitutes for determining the cause of symptoms.

Bacterial Vaginosis

BV is a vaginal dysbiosis characterized by reduced Lactobacillus predominance, increased concentrations of anaerobic organisms, and frequently a polymicrobial biofilm. It is not simply a Gardnerella infection, and Gardnerella culture should not be used diagnostically.[6,15]

BV can be diagnosed with Amsel criteria or Nugent scoring. Amsel criteria require at least three of four findings: homogeneous thin discharge, clue cells, vaginal pH greater than 4.5, and a fishy odor before or after potassium hydroxide. Nugent scoring from Gram stain is a laboratory reference method. Validated NAATs are useful in symptomatic patients, particularly when microscopy is unavailable or equivocal.[6,12,15]

Initial Treatment

Treatment is recommended for symptomatic BV. CDC-recommended regimens are metronidazole 500 mg orally twice daily for 7 days, metronidazole gel 0.75% intravaginally once daily for 5 days, or clindamycin cream 2% intravaginally at bedtime for 7 days. Direct comparative data do not establish oral therapy as superior to topical therapy, including for pregnancy outcomes, so regimen selection should be individualized.[6]

Alternative regimens include oral clindamycin, clindamycin ovules, secnidazole, and tinidazole. Secnidazole provides a single-dose option and is FDA approved for BV in female patients 12 years and older, but CDC lists it as an alternative regimen because of cost and less long-term outcomes experience than recommended regimens.[6,26]

Recurrent BV

Recurrent BV is common. After a first recurrence, retreatment with the same recommended regimen or use of a different recommended regimen is reasonable. For multiple recurrences, suppressive metronidazole gel or vaginal suppositories can reduce recurrence during use, but benefit often does not persist after discontinuation. Selected regimens that incorporate an oral nitroimidazole, intravaginal boric acid, and suppressive metronidazole have limited supporting data and warrant careful counseling. Routine over-the-counter probiotics should not replace guideline-supported therapy.[6,15]

Partner Management

Partner management is evolving and requires explicit distinction between older federal guidance and newer specialty guidance. CDC’s 2021 BV guideline states that routine treatment of sex partners is not recommended, reflecting trials available at that time.[6]

The 2025 StepUp open-label randomized trial studied monogamous heterosexual couples. Women received recommended BV treatment, while male partners in the intervention group received oral metronidazole 400 mg twice daily plus topical clindamycin 2% cream applied to penile skin twice daily for 7 days. BV recurrence within 12 weeks was lower with concurrent partner treatment than with treatment of the woman alone. The study was stopped early after a prespecified data and safety review, and adverse effects among treated men included nausea, headache, and metallic taste.[17]

Following these findings, ACOG issued a 2025 Clinical Practice Update recommending consideration of concurrent sexual partner therapy for adult patients with recurrent symptomatic BV. ACOG supports combined oral and topical antimicrobial treatment for male partners in this setting and shared decision-making for patients with same-sex partners and for selected patients with a first symptomatic episode. Evidence remains limited for nonmonogamous relationships, asymptomatic BV, and several partner populations.[2,3]

Clinicians should therefore avoid both extremes: continuing to state that partner therapy is never recommended and presenting it as universal care for every BV episode. The decision should account for recurrence pattern, partner anatomy and relationship context, contraindications, adherence, adverse effects, antimicrobial exposure, local guidance, and patient preferences. Current partners should be involved when concurrent therapy is selected.

Trichomoniasis

Trichomoniasis is a sexually transmitted infection caused by Trichomonas vaginalis. It may present with discharge, odor, pruritus, dysuria, dyspareunia, vulvar irritation, or cervicitis, but many infections are asymptomatic. Symptoms overlap with BV and VVC and should not be used to diagnose or exclude infection.[7,14]

Diagnosis

NAAT is preferred when available. Wet-mount microscopy can be used at the point of care, but sensitivity is limited and depends on immediate examination and operator skill. Cervical cytology is not diagnostic. If T. vaginalis is reported incidentally on a Pap test, confirmation with a sensitive diagnostic test is appropriate when feasible.[7]

Treatment

For women, CDC recommends metronidazole 500 mg orally twice daily for 7 days. Randomized evidence found lower repeat positivity at a 4-week test-of-cure visit with this regimen than with a single 2-g dose. For men, metronidazole 2 g orally once remains the recommended regimen. Tinidazole 2 g orally once is an alternative for women and men. Nitroimidazoles are the only medication class with clinically demonstrated efficacy against T. vaginalis. Metronidazole gel is not recommended because it does not achieve adequate concentrations in the urethra and perivaginal glands.[7,13,14]

Secnidazole 2 g orally once is FDA approved for trichomoniasis in patients 12 years and older and requires simultaneous treatment of sexual partners under the label. It is not listed as a preferred CDC regimen in the 2021 STI guideline, so use should account for guideline positioning, pregnancy and lactation considerations, cost, and antimicrobial stewardship.[7,26]

Partner Management and Follow-Up

Concurrent treatment of current sex partners is essential. Patients should abstain from sex until they and their partners have completed therapy and symptoms have resolved. Testing for HIV, syphilis, gonorrhea, and chlamydia should be performed when trichomoniasis is diagnosed. Retesting is recommended for all sexually active women approximately 3 months after treatment because repeat infection is common. Evidence is insufficient to support routine retesting of men.[7]

Persistent or recurrent trichomoniasis should be assessed systematically. The clinician should review adherence, vomiting after dosing, re-exposure to an untreated partner, and whether the correct regimen was used. If reinfection and nonadherence are unlikely, antimicrobial resistance should be considered. NAAT should not be performed earlier than 3 weeks after treatment completion because residual nucleic acid can produce a positive result. CDC susceptibility testing and expert consultation are appropriate for suspected nitroimidazole-resistant T. vaginalis.[7]

Medication and Safety Considerations

Medication selection should reflect the confirmed or strongly suspected diagnosis, pregnancy status, comorbidities, concomitant drugs, adherence feasibility, recurrence pattern, and product-specific labeling. The shortest regimen is not necessarily the most appropriate regimen.

Fluconazole

Before oral fluconazole is prescribed, clinicians should review pregnancy status, hepatic disease, renal function, QT risk, and interacting medications. Fluconazole inhibits multiple CYP pathways and can increase exposure to warfarin, certain sulfonylureas, phenytoin, calcineurin inhibitors, and other drugs. Some combinations associated with QT prolongation are contraindicated or require avoidance and monitoring. Renal dose adjustment may be necessary for repeated dosing in impaired renal function.[5,21]

Metronidazole

Metronidazole requires attention to nitroimidazole hypersensitivity, recent disulfiram use, warfarin interaction, lithium toxicity risk, neurologic adverse effects, hepatic impairment, severe renal dysfunction with metabolite accumulation, and Cockayne syndrome. Current DailyMed labeling contraindicates systemic metronidazole in Cockayne syndrome because severe irreversible hepatotoxicity and fatal acute liver failure have been reported.[24]

Alcohol counseling requires nuance. CDC’s BV guideline concludes that convincing evidence of a disulfiram-like interaction is lacking and considers abstinence unnecessary. Many current U.S. metronidazole product labels, however, continue to instruct patients to avoid alcohol and propylene glycol during treatment and for at least 3 days afterward. Clinicians should recognize this discrepancy and counsel according to the specific product label, institutional policy, and clinical context.[6,24]

Tinidazole

Tinidazole is an alternative nitroimidazole for BV and trichomoniasis. It should be avoided in pregnancy under CDC guidance because human data are limited and animal data raise concern. Labeling instructs patients to avoid alcohol or propylene glycol during therapy and for 3 days afterward and to interrupt breastfeeding during therapy and for 72 hours after the last dose. Neurologic adverse effects, blood dyscrasias, and interactions with warfarin, lithium, calcineurin inhibitors, and selected anticonvulsants warrant consideration.[7,25]

Clindamycin Vaginal Products

Vaginal clindamycin can weaken latex or rubber barrier products because of oil-based excipients. The interval varies by formulation: some clindamycin phosphate cream labels advise avoiding latex condoms and diaphragms for 72 hours after treatment, while the single-dose Clindesse product advises 5 days. Product-specific labeling should therefore be checked. Vaginal formulations also carry warnings for diarrhea, bloody diarrhea, and Clostridioides difficile-associated colitis, although systemic exposure is lower than with oral therapy.[6,27,28]

Secnidazole

Secnidazole is FDA approved as a single 2-g dose for BV in female patients 12 years and older and for trichomoniasis in patients 12 years and older. The label contraindicates use in patients with Cockayne syndrome and advises against breastfeeding for 96 hours after administration. For trichomoniasis, sexual partners should receive the same dose at the same time.[26]

Table 2. Treatment Overview for Common Infectious Vaginitis

Diagnosis	Usual first-line approach	Key safety and selection issues	Follow-up
Uncomplicated VVC, nonpregnant	Short-course topical azole or fluconazole 150 mg orally once	Exclude pregnancy before oral or newer systemic agents; review interactions, hepatic disease, renal function, and QT risk	Reevaluate persistent symptoms or recurrence within 2 months
VVC in pregnancy	Topical azole for 7 days	Do not use oral fluconazole for VVC in pregnancy	Reassess if symptoms persist
Recurrent C. albicans VVC	Confirm diagnosis and species; extended induction followed by maintenance fluconazole when appropriate	Consider susceptibility testing if culture-positive despite maintenance; newer agents have major reproductive restrictions	Specialist input for resistant, refractory, or non-albicans disease
Symptomatic BV	Oral metronidazole, metronidazole gel, or clindamycin cream	No established superiority of oral over topical therapy; review nitroimidazole and barrier-product precautions	No routine follow-up if symptoms resolve
Recurrent BV	Retreatment or alternate recommended regimen; suppressive strategies for multiple recurrences	Benefits may not persist after suppression; consider ACOG 2025 partner-therapy guidance in selected patients	Reevaluate recurrence and consider specialist input
Trichomoniasis in women	Metronidazole 500 mg orally twice daily for 7 days	Treat current partners; evaluate pregnancy, allergy, interactions, and adherence	Retest sexually active women at approximately 3 months
Trichomoniasis in men	Metronidazole 2 g orally once	Treat current partners and assess re-exposure if symptoms persist	Routine retesting is not supported by sufficient evidence

Practical Primary Care Algorithm

Step 1: Identify patients who need broader evaluation. Fever, pelvic pain, cervical motion or adnexal tenderness, pregnancy-related concern, genital ulceration, postmenopausal bleeding, severe vulvar disease, or suspected foreign body should move the clinician away from routine vaginitis treatment and toward appropriate pelvic, STI, pregnancy, or dermatologic evaluation.

Step 2: Obtain diagnostic samples. For symptomatic patients, measure vaginal pH and perform microscopy when available and reliable. When microscopy is negative, unavailable, or discordant with symptoms, use an appropriate NAAT, validated molecular vaginitis panel, Gram stain, or fungal culture according to the suspected diagnosis.

Step 3: Treat the confirmed condition. Use topical azoles or oral fluconazole for appropriate nonpregnant patients with uncomplicated VVC. Use a recommended metronidazole or clindamycin regimen for symptomatic BV. Use 7-day oral metronidazole for trichomoniasis in women and ensure treatment of current partners. Avoid repeated empiric therapy without diagnostic reconsideration.

Step 4: Plan follow-up. Advise return for persistent symptoms, recurrence soon after treatment, new pelvic pain or fever, pregnancy, medication intolerance, or incomplete partner treatment in trichomoniasis. Retest sexually active women with trichomoniasis at approximately 3 months.

Special Populations

Pregnancy

Symptomatic BV should be treated during pregnancy. CDC reports that oral therapy has not been shown to be superior to topical therapy for cure or prevention of adverse pregnancy outcomes. Routine screening of asymptomatic pregnant patients for BV solely to prevent preterm birth is not recommended because trial results have been mixed or negative. VVC should be treated with a 7-day topical azole regimen. Symptomatic pregnant patients with trichomoniasis should be tested and treated regardless of pregnancy stage, with counseling about partner treatment and prevention of reinfection.[5-7]

Diabetes and Immunocompromise

Poorly controlled diabetes, HIV, corticosteroid therapy, transplant immunosuppression, and other immunocompromising conditions increase the likelihood of complicated candidiasis or reduced response to short-course therapy. Confirmatory testing, species identification, 7 to 14 days of conventional treatment, and closer follow-up may be needed.[5]

Women with HIV have higher rates of vaginal Candida colonization and symptomatic VVC, particularly with greater immunosuppression, but VVC treatment generally follows the same principles used for women without HIV. Women with HIV and trichomoniasis should receive metronidazole 500 mg orally twice daily for 7 days and should be retested after treatment.[5,7]

Adolescents and Sexual Health

Adolescents and young adults require confidential, developmentally appropriate sexual health history taking, pregnancy assessment when relevant, STI testing, and partner services. Expedited partner therapy may have a role in trichomoniasis where legally permitted. Clinicians should follow state law and local public health guidance.[7]

Postmenopausal Patients

Postmenopausal symptoms may reflect genitourinary syndrome of menopause, dermatologic disorders, irritant exposures, lichen sclerosus, inflammatory vaginitis, malignancy, or infection. Vaginal pH is often elevated after menopause, reducing its specificity for BV or trichomoniasis. Persistent symptoms, bleeding, visible vulvar lesions, or repeatedly negative infectious testing should prompt examination and appropriate referral.[1,10]

Limitations of the Evidence

Evidence is strong for the principal regimens used for uncomplicated VVC, symptomatic BV, and trichomoniasis in women. Evidence is less certain for recurrent BV, non-albicans VVC, probiotics, microbiome-directed interventions, and the optimal real-world placement of every commercial molecular vaginitis panel. Diagnostic performance varies by assay, specimen type, symptomatic status, patient population, and laboratory validation.[5-8,12,15,16]

Partner therapy for BV illustrates the difficulty of integrating new evidence. The StepUp trial provides important randomized evidence in monogamous heterosexual couples, and ACOG has incorporated the findings into focused guidance. Generalizability to other relationship structures, partner anatomies, asymptomatic BV, and universal first-episode treatment remains uncertain. A 2026 meta-analysis pooling older heterogeneous trials with the StepUp study did not find an overall statistically significant reduction in recurrence, underscoring the importance of regimen, adherence, population, and study design when interpreting the literature. Current recommendations should therefore be applied to the populations and circumstances they address rather than generalized without qualification.[2,3,17,29]

Future Directions

Future improvements are likely to include faster point-of-care molecular testing, better species-level Candida diagnosis, more durable strategies for preventing recurrent BV, clearer management of non-albicans VVC, and more inclusive partner-treatment research. Microbiome-based interventions remain investigational and should be judged by durable symptom resolution, reduced recurrence, safety, and patient-centered outcomes rather than microbiologic change alone.

 

References

1. American College of Obstetricians and Gynecologists. (2020). Vaginitis in nonpregnant patients: ACOG Practice Bulletin, Number 215. Obstetrics & Gynecology, 135(1), e1-e17. https://doi.org/10.1097/AOG.0000000000003604. PMID: 31856123.

2. American College of Obstetricians and Gynecologists. (2025). Concurrent sexual partner therapy to prevent bacterial vaginosis recurrence: Clinical Practice Update. Obstetrics & Gynecology, 146(6), e111-e114. https://doi.org/10.1097/AOG.0000000000006102. PMID: 41100865.

3. American College of Obstetricians and Gynecologists. (2025, October 17). ACOG recommends concurrent sexual partner treatment for recurrent bacterial vaginosis for the first time. https://www.acog.org/news/news-releases/2025/10/acog-recommends-concurrent-sexual-partner-treatment-recurrent-bacterial-vaginosis-first-time

4. Centers for Disease Control and Prevention. (2021). Diseases characterized by vulvovaginal itching, burning, irritation, odor, or discharge: STI Treatment Guidelines. https://www.cdc.gov/std/treatment-guidelines/vaginal-discharge.htm

5. Centers for Disease Control and Prevention. (2021). Vulvovaginal candidiasis: STI Treatment Guidelines. https://www.cdc.gov/std/treatment-guidelines/candidiasis.htm

6. Centers for Disease Control and Prevention. (2021). Bacterial vaginosis: STI Treatment Guidelines. https://www.cdc.gov/std/treatment-guidelines/bv.htm

7. Centers for Disease Control and Prevention. (2021). Trichomoniasis: STI Treatment Guidelines. https://www.cdc.gov/std/treatment-guidelines/trichomoniasis.htm

8. World Health Organization. (2024). Recommendations for the treatment of Trichomonas vaginalis, Mycoplasma genitalium, Candida albicans, bacterial vaginosis and human papillomavirus (anogenital warts). https://www.who.int/publications/i/item/9789240096370

9. Workowski, K. A., Bachmann, L. H., Chan, P. A., Johnston, C. M., Muzny, C. A., Park, I., Reno, H., Zenilman, J. M., & Bolan, G. A. (2021). Sexually transmitted infections treatment guidelines, 2021. MMWR Recommendations and Reports, 70(4), 1-187. https://doi.org/10.15585/mmwr.rr7004a1. PMID: 34292926.

10. Marnach, M. L., Wygant, J. N., & Casey, P. M. (2022). Evaluation and management of vaginitis. Mayo Clinic Proceedings, 97(2), 347-358. https://doi.org/10.1016/j.mayocp.2021.09.022. PMID: 35120697.

11. Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., Zaoutis, T. E., & Sobel, J. D. (2016). Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 62(4), e1-e50. https://doi.org/10.1093/cid/civ933. PMID: 26679628.

12. Schwebke, J. R., Taylor, S. N., Ackerman, R., Schlaberg, R., Quigley, N. B., Gaydos, C. A., Chavoustie, S. E., Nyirjesy, P., Remillard, C. V., Estes, P., McKinney, B., Getman, D. K., & Clark, C. (2020). Clinical validation of the Aptima bacterial vaginosis and Aptima Candida/Trichomonas vaginitis assays: Results from a prospective multicenter clinical study. Journal of Clinical Microbiology, 58(2), e01643-19. https://doi.org/10.1128/JCM.01643-19. PMID: 31748322.

13. Kissinger, P., Muzny, C., Mena, L., Lillis, R., Schwebke, J., Beauchamps, L., Taylor, S. N., Schmidt, N., Myers, L., Augostini, P., Secor, W. E., Bradic, M., Carlton, J. M., & Martin, D. H. (2018). Single-dose versus 7-day-dose metronidazole for the treatment of trichomoniasis in women: An open-label, randomized controlled trial. The Lancet Infectious Diseases, 18(11), 1251-1259. https://doi.org/10.1016/S1473-3099(18)30423-7. PMID: 30297322.

14. Kissinger, P. J., Gaydos, C. A., Seña, A. C., McClelland, R. S., Soper, D., Secor, W. E., Legendre, D., Workowski, K. A., & Muzny, C. A. (2022). Diagnosis and management of Trichomonas vaginalis: Summary of evidence reviewed for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines. Clinical Infectious Diseases, 74(Suppl. 2), S152-S161. https://doi.org/10.1093/cid/ciac030. PMID: 35416973.

15. Muzny, C. A., Balkus, J., Mitchell, C., Sobel, J. D., Workowski, K., Marrazzo, J., & Schwebke, J. R. (2022). Diagnosis and management of bacterial vaginosis: Summary of evidence reviewed for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines. Clinical Infectious Diseases, 74(Suppl. 2), S144-S151. https://doi.org/10.1093/cid/ciac021. PMID: 35416968.

16. Nyirjesy, P., Brookhart, C., Lazenby, G., Schwebke, J. R., & Sobel, J. D. (2022). Vulvovaginal candidiasis: A review of the evidence for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines. Clinical Infectious Diseases, 74(Suppl. 2), S162-S168. https://doi.org/10.1093/cid/ciab1057. PMID: 35416967.

17. Vodstrcil, L. A., Plummer, E. L., Fairley, C. K., Hocking, J. S., Law, M. G., Petoumenos, K., Bateson, D., Murray, G. L., Donovan, B., Chow, E. P. F., Chen, M. Y., Kaldor, J. M., Bradshaw, C. S., & the StepUp Team. (2025). Male-partner treatment to prevent recurrence of bacterial vaginosis. The New England Journal of Medicine, 392(10), 947-957. https://doi.org/10.1056/NEJMoa2405404. PMID: 40043236.

18. Sobel, J. D., Wiesenfeld, H. C., Martens, M., Danna, P., Hooton, T. M., Rompalo, A., Sperling, M., Livengood, C., Horowitz, B., Von Thron, J., Edwards, L., Panzer, H., & Chu, T. C. (2004). Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. The New England Journal of Medicine, 351(9), 876-883. https://doi.org/10.1056/NEJMoa033114. PMID: 15329425.

19. Sobel, J. D., Donders, G., Degenhardt, T., Person, K., Curelop, S., Ghannoum, M., & Brand, S. R. (2022). Efficacy and safety of oteseconazole in recurrent vulvovaginal candidiasis. NEJM Evidence, 1(8), EVIDoa2100055. https://doi.org/10.1056/EVIDoa2100055. PMID: 38319878.

20. Goje, O., Azie, N. E., Angulo, D. A., Sobel, R., Nyirjesy, P., & Sobel, J. D. (2025). A phase 3, multicenter, randomized, placebo-controlled trial of monthly oral ibrexafungerp to reduce the incidence of recurrent vulvovaginal candidiasis. American Journal of Obstetrics and Gynecology, 233(6), 617.e1-617.e18. https://doi.org/10.1016/j.ajog.2025.07.040. PMID: 40752754.

21. DailyMed. (2025). Fluconazole tablet, prescribing information. U.S. National Library of Medicine. Retrieved July 28, 2026, from https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=06f8f4b9-5289-2d59-e063-6294a90a7209

22. DailyMed. (2024). BREXAFEMME (ibrexafungerp) tablets, prescribing information. U.S. National Library of Medicine. Retrieved July 28, 2026, from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c33be3a1-c4fd-512c-e053-2995a90a63eb

23. DailyMed. (2026). VIVJOA (oteseconazole) capsules, prescribing information. U.S. National Library of Medicine. Retrieved July 28, 2026, from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e21d5008-800e-4417-927f-14340341865f

24. DailyMed. (2026). Metronidazole tablet, prescribing information. U.S. National Library of Medicine. Retrieved July 28, 2026, from https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c90da73c-e48e-411a-bd75-0b107f1141cc

25. DailyMed. (2021). TINDAMAX (tinidazole) tablets, prescribing information. U.S. National Library of Medicine. Retrieved July 28, 2026, from https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a0d01539-8413-4703-94cc-d221918630a1

26. DailyMed. (2025). SOLOSEC (secnidazole) oral granules, prescribing information. U.S. National Library of Medicine. Retrieved July 28, 2026, from https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=056485b6-8bba-4a21-ae00-cdb4e7ae4bfa

27. DailyMed. (2009). Clindamycin phosphate vaginal cream 2%, prescribing information. U.S. National Library of Medicine. Retrieved July 28, 2026, from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=706dd0b6-367c-4950-88fe-7a6c0661c2b9

28. DailyMed. (2024). CLINDESSE (clindamycin phosphate) vaginal cream, prescribing information. U.S. National Library of Medicine. Retrieved July 28, 2026, from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fe8bb204-f173-44fe-803b-b08f2ec5aa31

29. Vieira, L. L. P., Suruagy-Motta, R. F. O., Bomfim, J. Q., Teixeira, A. L. D. S., Farias, E. H., Santos, K. D. A., Donato, K. O., Silva, L. D., Rohden, C. A. H., Lemos, M., & Lopes, L. P. (2026). The efficacy of male partner treatment to prevent recurrence of bacterial vaginosis: A systematic review with meta-analysis of randomized controlled trials. European Journal of Obstetrics & Gynecology and Reproductive Biology, 321, 115047. https://doi.org/10.1016/j.ejogrb.2026.115047. PMID: 41780137.